Trial Profile
Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 17 Mar 2021 Status changed from completed to discontinued.
- 31 Mar 2020 Status changed from active, no longer recruiting to completed.
- 23 May 2019 Planned End Date changed from 1 Nov 2023 to 30 Nov 2023.